Allo HSCT Using RIC for Hematological Diseases
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Burkitt's Lymphoma
- Acute Lymphocytic Leukemia
- Non Hodgkin's Lymphoma
- Prolymphocytic Leukemia
- Acute Myelogenous Leukemia
- B Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Follicular Lymphoma
- Small Lymphocytic Lymphoma
- Plasma Cell Leukemia
- Hematological Diseases
- Lymphoblastic Lymphoma
- Lymphoplasmacytic Lymphoma
- Myeloproliferative Syndromes
- Multiple Myeloma
- Mantle Cell Lymphoma
- Myelodysplastic Syndromes
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Younger than 75 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02661035
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Erica Warlick, MD Masonic Cancer Center, University of Minnesota
Get Well Soon